Xilio Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

Rhea-AI Summary

Xilio Therapeutics (Nasdaq: XLO), a clinical-stage biotechnology company focused on developing tumor-activated immuno-oncology therapies, has announced its upcoming participation in the TD Cowen 45th Annual Health Care Conference.

The company's president and chief executive officer, René Russo, Pharm.D., will engage in a fireside chat on Monday, March 3, 2025, at 9:50 am EST.

Interested parties can access a live webcast of the presentation through the 'Events & Presentations' section of Xilio's investor relations website at ir.xiliotx.com. The webcast recording will remain available on the website for 30 days after the presentation.

News Market Reaction – XLO

-5.13%

-5.13% Session move

In the trading session that priced this news, XLO declined 5.13%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that René Russo, Pharm.D., president and chief executive officer, will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025 at 9:50 am EST.

A live webcast can be accessed under “Events & Presentations” in the Investors & Media section of the Xilio Therapeutics website at https://ir.xiliotx.com/. A replay of the webcast will be archived on the website for 30 days following the presentation.

About Xilio Therapeutics

Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment. Learn more by visiting www.xiliotx.com and follow us on LinkedIn (Xilio Therapeutics, Inc.).

This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.

Investor and Media Contact

Scott Young
Vice President, Investor Relations and Corporate Communications
investors@xiliotx.com

FAQ

When is Xilio Therapeutics (XLO) presenting at the TD Cowen Health Care Conference 2025?

Xilio Therapeutics will present at the TD Cowen Health Care Conference on Monday, March 3, 2025, at 9:50 am EST.

How can investors watch Xilio Therapeutics' (XLO) TD Cowen conference presentation?

Investors can watch the presentation via live webcast through the 'Events & Presentations' section of Xilio's investor relations website at ir.xiliotx.com.

How long will Xilio Therapeutics' (XLO) TD Cowen conference presentation be available for replay?

The webcast replay will be archived and available on Xilio's website for 30 days following the presentation.

What type of therapies is Xilio Therapeutics (XLO) developing?

Xilio Therapeutics is developing tumor-activated immuno-oncology therapies for people living with cancer.